Brought to you by 
Abuse-deterring technology developer Egalet nets $53.9mm in IPO
30 Mar 2021
Executive Summary
UK biotech Egalet Corp. netted $53.9mm in its US initial public offering. The company sold 4.8mm shares (including the overallotment; and more than the 3.5mm planned) at $12, the mid-point of its $11-13 price range.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Abuse-deterring technology developer Egalet nets $53.9mm in IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice